Arndt Vogel· @ArndtVogel · X·· 2 天前评分70
正文 · 原文
TQB2102, a novel HER2 bispecific ADC, combined with bemotrizumab with or without capecitabine as 1L for HER2+ GC/GEJC: A phase II study
#ESMO26 #ESMOAmbassadors
👉 ORR: 69 vs 84% DCR 9
👉 mPFS: 12.7 vs 11.04 mo
🧐Supports combining CTx, ICI & Her2🎯 in 1L
@myESMO @ASCO
352 浏览 · 4 赞 · 2 转发 · 0 回复
会议摘要
2876RO按 Rapid oral 1: Gastrointestinal tumour, upper digestive 对上
TQB2102, a novel HER2 bispecific antibody-drug conjugate, combined with bemotrizumab with or without capecitabine as first-line therapy for HER2-positive advanced gastric/gastroesophageal junction cancer: A phase II study
https://esmocongress.esmo.org来源：Arndt Vogel · x.com